Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACME LaboratoriesDHA:ACMELAB 85 Debt-to-Equity is 0.85 as of Mar. 2026, which is 10% above its 10-year median of 0.77. GuruFocus rates DHA:ACMELAB with a GF Score™ of 85/100 and a GF Value™ of BDT127.93 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 811 Drug Manufacturers companies, ACME Laboratories ranks worse than 82.49% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for ACME Laboratories's Debt-to-Equity or its related term are showing as below:
DHA:ACMELAB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.56 Med: 0.77 Max: 0.98
Current: 0.85
During the past 9 years, the highest Debt-to-Equity Ratio of ACME Laboratories was 0.98. The lowest was 0.56. And the median was 0.77.
DHA:ACMELAB's Debt-to-Equity is ranked worse than 82.49% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs DHA:ACMELAB: 0.85
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
ACME Laboratories Debt-to-Equity Related Terms
ACME Laboratories Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for ACME Laboratories's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ACMELAB vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ACME Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACME Laboratories Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ACME Laboratories's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where ACME Laboratories's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACME Laboratories (DHA:ACMELAB) has a Debt-to-Equity of 0.85 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ACME Laboratories and its competitors. This is 10% above median its historical median of 0.77. Over the past decade, ACME Laboratories' Debt-to-Equity has ranged from 0.56 to 0.98. According to the industry distribution chart, ACME Laboratories ranks #669 out of 811 companies in the Drug Manufacturers industry, placing it in the top 82.5%.
Is ACME Laboratories' Debt-to-Equity too high?
ACME Laboratories' current Debt-to-Equity of 0.85 is 10% above median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 0.98. The Drug Manufacturers industry median Debt-to-Equity is 0.28. ACME Laboratories' value of 0.85 is 203.6% above this industry median. Based on the distribution chart, ACME Laboratories ranks #669 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ACME Laboratories has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, ACME Laboratories ranks #669 out of 811 companies for Debt-to-Equity. This places ACME Laboratories in the lower half of its industry. The industry median Debt-to-Equity is 0.28. ACME Laboratories' value of 0.85 is 203.6% above this benchmark. Historically, ACME Laboratories' own Debt-to-Equity has ranged from 0.56 to 0.98 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.28, ACME Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current Debt-to-Equity of 0.85 is 203.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on ACME Laboratories and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current Debt-to-Equity is 0.85, which is 10% above median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT127.93, compared to a current price of BDT79.70 — trading 37.7% below its estimated fair value. The current Debt-to-Equity is 0.85, which is 10% above median its 10-year median of 0.77 and 203.6% above the Drug Manufacturers industry median of 0.28. ACME Laboratories' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current Debt-to-Equity is 0.85 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?
Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued.
The current stock price of BDT79.70 is trading 37.7% below its estimated GF Value™ of BDT127.93.
GuruFocus considers ACME Laboratories to be Possible Value Trap.
Key valuation signals for DHA:ACMELAB:
Debt-to-Equity: 0.85 (10% above median its 10-year median of 0.77)
GF Value™: BDT127.93 vs. price of BDT79.70 (37.7% below fair value)
Industry Position: 203.6% above the Drug Manufacturers median (#669 of 811)
No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
85GF Score
Get the complete analysis for DHA:ACMELAB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ACMELAB has been successfully added to your 
